132628-16-1

Basic information

• Product Name: N2-Phenylacetyl guanosine
• Synonyms: N2-PHENYLACETYL RIBONUCLEOSIDE GUANOSINE;N-(Phenylacetyl)guanosine;N-(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxyMethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-phenylacetaMide;N2-Phenylacetyl guanosine N-(9-((2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyMethyl)-tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-phenylacetaMide;N-(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-pur;N2-Phenylacetyl Gr;Phenylacetylguanosine;N-(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-
• CAS NO: 132628-16-1
• Molecular Formula: C₁₈H₁₉N₅O₆
• Molecular Weight: 401.38
• EINECS: 1312995-182-4
• Mol File: 132628-16-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 189℃
• Appearance: /
• Density: 1.73
• Refractive Index: 1.784
• Storage Temp.: 2-8°C
• PKA: 8.80±0.20(Predicted)
• CAS DataBase Reference: N2-Phenylacetyl guanosine(CAS DataBase Reference)
• NIST Chemistry Reference: N2-Phenylacetyl guanosine(132628-16-1)
• EPA Substance Registry System: N2-Phenylacetyl guanosine(132628-16-1)

Safety Data

• Hazardous Substances Data: 132628-16-1(Hazardous Substances Data)

Usage

General Description

N2-Phenylacetyl guanosine is a modified nucleoside derivative of guanosine, with a phenylacetyl group attached to the nitrogen-2 position of the guanine base. This chemical modification enhances the stability and selectivity of the compound, making it a potentially useful tool in nucleic acid research and as a potential therapeutic agent. N2-Phenylacetyl guanosine has been studied for its ability to inhibit viral replication and as an anti-cancer agent, showing promising results in preclinical studies. Additionally, this modified nucleoside has been investigated for its potential application in the development of nucleoside analogs for RNA and DNA modification, offering potential for the creation of novel nucleic acid-based technologies.

InChI:InChI=1/C18H19N5O6/c24-7-10-13(26)14(27)17(29-10)23-8-19-12-15(23)21-18(22-16(12)28)20-11(25)6-9-4-2-1-3-5-9/h1-5,8,10,13-14,17,24,26-27H,6-7H2,(H2,20,21,22,25,28)/t10-,13-,14-,17-/m1/s1

Upstream product

• 103-80-0 phenylacetyl chloride 
• 118-00-3 G 
• 263009-03-6 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-2-N-(phenylacetyl)guanosine 
• 147490-73-1 2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-2-N-(phenylacetyl)guanosine 
• 64656-29-7 1-phenylacetoxy-1H-benzotriazole 

Downstream Products

• 147490-73-1 2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-2-N-(phenylacetyl)guanosine 
• 1053615-24-9 N-(9-{(2R,3R,3aR,9aR)-3-[1-(2-Fluoro-phenyl)-4-methoxy-piperidin-4-yloxy]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-phenyl-acetamide 
• 147490-76-4 2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-2-N-(phenylacetyl)-5'-O-(9-phenylxanthen-9-yl)guanosine 
• 147490-80-0 2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-2-N-(phenylacetyl)-5'-O-(9-phenylxanthen-9-yl)guanosine 3'-<(2-cyanoethyl)-N,N-diisopropylphosphoroamidite> 
• 132628-24-1 N-(9-{(2R,3R,4S,5S)-3,4-Dihydroxy-5-[9-(4-methoxy-phenyl)-9H-xanthen-9-ylsulfanylmethyl]-tetrahydro-furan-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-phenyl-acetamide 
• 1013631-14-5 9-(2',3'-O-benzylidene-β-D-ribofuranosyl)-2-N-(phenylacetyl)-guanine 
• 163889-47-2 N-{9-[(2R,3R,4R,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-3-(2-trimethylsilanyl-ethoxymethoxy)-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenyl-acetamide 
• 163889-39-2 N-{9-[(4aR,6R,7R,7aR)-2,2-Di-tert-butyl-7-(2-trimethylsilanyl-ethoxymethoxy)-tetrahydro-furo[3,2-d][1,3,2]dioxasilin-6-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenyl-acetamide 
• 163889-43-8 N-{9-[(2R,3R,4R,5R)-4-Hydroxy-5-hydroxymethyl-3-(2-trimethylsilanyl-ethoxymethoxy)-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenyl-acetamide 
• 309967-59-7 2'-O-[bis(2-cyano-1,1-dimethylethoxy)thiophosphoryl]-5'-O-(4,4'-dimethoxytrityl)-2-N-phenylacetyl-6-O-(2-cyanoethyl)guanosine 
• 1053249-50-5 6-S-(2-cyanoethyl)-2'-O-(tert-butyldimethylsilyl)-2-N-phenylacetyl-6-thioguanosine 3',5'-bisphosphate tetrakis(2-cyanoethyl) ester 
• 309967-55-3 2'-O-[bis(2-cyano-1,1-dimethylethoxy)thiophosphoryl]-2-N-phenylacetyl-6-O-(2-cyanoethyl)guanosine 
• 309967-52-0 3',5'-O-(di-tert-butylsilanediyl)-2-N-phenylacetyl-6-O-(2-cyanoethyl)guanosine 

Relevant articles and documents

Preparation N 2-phenylacetyl-D-guanylin improved method (by machine translation)

The invention relates to a preparation N 2-phenylacetyl-D-guanylin improved method, to the three a-based silicon-based protection in-quanosine D, adding phenyllacetyl chloride, 1-hydroxy benzotriazole, acetonitrile and reaction solution of pyri

Some observations relating to the use of 1-aryl-4-alkoxypiperidin-4-yl groups for the protection of the 2′-hydroxy functions in the chemical synthesis of oligoribonucleotides

The comparative rates of acid-catalysed removal often 1-aryl-4-methoxypiperidin-4-yl 8 (R = Me) [including the previously reported Ctmp 5 and Fpmp 6] protecting groups for the 2′-hydroxy functions in oligoribonucleotide synthesis are discussed. These studies have led to the development of the 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) protecting group 8 (R = Et, R1 = R2 = H, R3 = Cl) which is both more stable than the Ctmp and Fpmp groups at pH 0.5 and more labile at pH 3.75. The influence of the ribonucleoside aglycone on the stability of the 2′-O-Fpmp and 2′-O-Ctmp protecting groups both at low and high pH is examined. The Royal Society of Chemistry 2000.

Base-modified enzymatic nucleic acid

An enzymatic nucleic acid having a modification selected from pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyluracil, dihydrouracil, naphthyl, 6-methyl-uracil and aminophenyl.